8 results about "Methyl xanthine" patented technology

The present invention relates to an oral extended-release dosage form of 7-methylxanthine (7-MX) or a pharmaceutically acceptable salt thereof. The dosage form is designed for twice-daily administration and provides controlled release of the active agent, achieving pharmacokinetic characteristics including sustained plasma concentrations and reduced fluctuation compared to immediate-release formulations. The invention further relates to the use of such dosage forms in the treatment of myopia, wherein the extended-release characteristics enhance therapeutic effectiveness in myopia.

The present invention discloses compositions comprising methylxanthines in combination with disaccharides derived from enzymatic conversion of sucrose. More particularly, the present invention discloses compositions comprising methylxanthines and disaccharides derived from enzymatic conversion of sucrose selected from turanose, leucrose, trehalulose and isomaltulose or in combinations thereof.

A fermentation process for the preparation of xanthine and xanthine derivatives. The disclosure generally relates to a fermentation process for the preparation of xanthine or xanthine derivatives such as 7-methylxanthine (7-MX), theobromine, theophylline, 3-methylxanthine or mixtures thereof. The process results in improved yield and increased efficiency on industrial scale compared to batch process of preparation.

The invention relates to the technical field of biological culture, and particularly discloses a culture medium for improving synthesis of unsaturated fatty acid in cell culture fat, which is used for solving the problem that the content of unsaturated fatty acid in the culture fat is not satisfactory. The differentiation culture medium comprises the following components: a basic culture medium, a specific porcine adipose-derived mesenchymal stem cell differentiation induction factor and an unsaturated fatty acid additive. Wherein the specific induction factors comprise but are not limited to factors such as insulin, dexamethasone, indometacin, 3-isobutyl-1-methylxanthine, rosiglitazone and the like. The unsaturated fatty acid additive comprises alpha-linolenic acid, and by adding the substances into the culture medium, the differentiation efficiency of the porcine adipose-derived mesenchymal stem cells and the directional synthesis of the unsaturated fatty acid in the cells can be improved. According to the improved differential culture medium, cell differentiation and unsaturated fatty acid synthesis are effectively promoted by optimizing components and proportions, and the improved differential culture medium has an important application prospect.

The present disclosure provides engineered microbial cells, compositions, and methods of use thereof for producing methylxanthines including theobromine and caffeine.

The present invention provides a combination of Bifidobacterium longum subsp. infantis, lacto- N-fucopentaose I (LNFP-I) and a HMO mixture for use in therapy by promoting the production of one or more beneficial metabolites selected from uridine, adenine, guanine, AMP, cAMP, 4-guanidinobutyric acid, p-hydroxyphenyllactic acid, acetyl-carnitine and 3-methylxanthine in the gastrointestinal tract of an infant or young child, wherein the HMO mixture consists of 2'- fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally 3-fucosyllactose (3FL) and / or lacto-N-neotetraose (LNnT).

The present invention relates to cocrystals of Methylxanthines with Stilbenoids as coformers, their polymorphic forms and to the process for preparation thereof. The debittering of Methylxanthines is carried out by co-crystallization using Stilbenoids as coformers. The invention further relates to the preparation of polymorphic forms of debittered cocrystals and their use in nutraceutical and pharmaceutical compositions.

The present disclosure provides engineered microbial cells, compositions, and methods of use thereof for producing methylxanthines including theobromine and caffeine.